ID   DHI1_HUMAN              Reviewed;         292 AA.
AC   P28845; B2R9Z1; D3DT89;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Corticosteroid 11-beta-dehydrogenase isozyme 1;
DE            EC=1.1.1.146;
DE   AltName: Full=11-beta-hydroxysteroid dehydrogenase 1;
DE            Short=11-DH;
DE            Short=11-beta-HSD1;
DE   AltName: Full=Short chain dehydrogenase/reductase family 26C member 1;
GN   Name=HSD11B1; Synonyms=HSD11, HSD11L, SDR26C1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Testis;
RX   PubMed=1885595;
RA   Tannin G.M., Agarwal A.K., Monder C., New M.I., White P.C.;
RT   "The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure,
RT   tissue distribution, and chromosomal localization.";
RL   J. Biol. Chem. 266:16653-16658(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12414862; DOI=10.1210/jc.2001-011375;
RA   Draper N., Echwald S.M., Lavery G.G., Walker E.A., Fraser R.,
RA   Davies E., Soerensen T.I.A., Astrup A., Adamski J., Hewison M.,
RA   Connell J.M., Pedersen O., Stewart P.M.;
RT   "Association studies between microsatellite markers within the gene
RT   encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body
RT   mass index, waist to hip ratio, and glucocorticoid metabolism.";
RL   J. Clin. Endocrinol. Metab. 87:4984-4990(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TOPOLOGY, GLYCOSYLATION, AND
RP   MUTAGENESIS OF LYS-5; 5-LYS-LYS-6; LYS-6; 18-TYR--TYR-21 AND
RP   19-TYR--TYR-21.
RX   PubMed=10497248; DOI=10.1074/jbc.274.40.28762;
RA   Odermatt A., Arnold P., Stauffer A., Frey B.M., Frey F.J.;
RT   "The N-terminal anchor sequences of 11beta-hydroxysteroid
RT   dehydrogenases determine their orientation in the endoplasmic
RT   reticulum membrane.";
RL   J. Biol. Chem. 274:28762-28770(1999).
RN   [8]
RP   INVOLVEMENT IN CRD.
RX   PubMed=12858176; DOI=10.1038/ng1214;
RA   Draper N., Walker E.A., Bujalska I.J., Tomlinson J.W., Chalder S.M.,
RA   Arlt W., Lavery G.G., Bedendo O., Ray D.W., Laing I., Malunowicz E.,
RA   White P.C., Hewison M., Mason P.J., Connell J.M., Shackleton C.H.L.,
RA   Stewart P.M.;
RT   "Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase
RT   type 1 and hexose-6-phosphate dehydrogenase interact to cause
RT   cortisone reductase deficiency.";
RL   Nat. Genet. 34:434-439(2003).
RN   [9]
RP   CATALYTIC ACTIVITY, TOPOLOGY, AND MUTAGENESIS OF 5-LYS-LYS-6; GLU-25;
RP   25-GLU-GLU-26; GLU-26 AND 35-LYS-LYS-36.
RX   PubMed=15152005; DOI=10.1074/jbc.M313666200;
RA   Frick C., Atanasov A.G., Arnold P., Ozols J., Odermatt A.;
RT   "Appropriate function of 11beta-hydroxysteroid dehydrogenase type 1 in
RT   the endoplasmic reticulum lumen is dependent on its N-terminal region
RT   sharing similar topological determinants with 50-kDa esterase.";
RL   J. Biol. Chem. 279:31131-31138(2004).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-123 AND ASN-162.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 24-292 IN COMPLEX WITH NADP
RP   AND SUBSTRATE ANALOG, AND SUBUNIT.
RX   PubMed=15513927; DOI=10.1074/jbc.M411104200;
RA   Hosfield D.J., Wu Y., Skene R.J., Hilgers M., Jennings A., Snell G.P.,
RA   Aertgeerts K.;
RT   "Conformational flexibility in crystal structures of human 11beta-
RT   hydroxysteroid dehydrogenase type I provide insights into
RT   glucocorticoid interconversion and enzyme regulation.";
RL   J. Biol. Chem. 280:4639-4648(2005).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 24-284 IN COMPLEXES WITH
RP   ADAMANTANE SULFONE AND SULFONAMIDE INHIBITORS, AND CATALYTIC ACTIVITY.
RX   PubMed=17070044; DOI=10.1016/j.bmcl.2006.10.008;
RA   Sorensen B., Winn M., Rohde J., Shuai Q., Wang J., Fung S., Monzon K.,
RA   Chiou W., Stolarik D., Imade H., Pan L., Deng X., Chovan L.,
RA   Longenecker K., Judge R., Qin W., Brune M., Camp H., Frevert E.U.,
RA   Jacobson P., Link J.T.;
RT   "Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:527-532(2007).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-292 IN COMPLEX WITH NADP
RP   AND INHIBITOR, SUBUNIT, AND CATALYTIC ACTIVITY.
RX   PubMed=17919905; DOI=10.1016/j.bmcl.2007.09.070;
RA   Yuan C., St Jean D.J. Jr., Liu Q., Cai L., Li A., Han N., Moniz G.,
RA   Askew B., Hungate R.W., Johansson L., Tedenborg L., Pyring D.,
RA   Williams M., Hale C., Chen M., Cupples R., Zhang J., Jordan S.,
RA   Bartberger M.D., Sun Y., Emery M., Wang M., Fotsch C.;
RT   "The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:6056-6061(2007).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 24-292 IN COMPLEX WITH NADP
RP   AND INHIBITOR.
RX   PubMed=18485702; DOI=10.1016/j.bmcl.2008.04.069;
RA   Wang H., Ruan Z., Li J.J., Simpkins L.M., Smirk R.A., Wu S.C.,
RA   Hutchins R.D., Nirschl D.S., Van Kirk K., Cooper C.B., Sutton J.C.,
RA   Ma Z., Golla R., Seethala R., Salyan M.E.K., Nayeem A.,
RA   Krystek S.R. Jr., Sheriff S., Camac D.M., Morin P.E., Carpenter B.,
RA   Robl J.A., Zahler R., Gordon D.A., Hamann L.G.;
RT   "Pyridine amides as potent and selective inhibitors of 11beta-
RT   hydroxysteroid dehydrogenase type 1.";
RL   Bioorg. Med. Chem. Lett. 18:3168-3172(2008).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 24-292 IN COMPLEX WITH NADP
RP   AND INHIBITOR.
RX   PubMed=18069989; DOI=10.1111/j.1747-0285.2007.00603.x;
RA   Hale C., Veniant M., Wang Z., Chen M., McCormick J., Cupples R.,
RA   Hickman D., Min X., Sudom A., Xu H., Matsumoto G., Fotsch C.,
RA   St Jean D.J. Jr., Wang M.;
RT   "Structural characterization and pharmacodynamic effects of an orally
RT   active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.";
RL   Chem. Biol. Drug Des. 71:36-44(2008).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 24-292 IN COMPLEX WITH NADP
RP   AND INHIBITOR.
RX   PubMed=18553955; DOI=10.1021/jm800310g;
RA   Julian L.D., Wang Z., Bostick T., Caille S., Choi R.,
RA   DeGraffenreid M., Di Y., He X., Hungate R.W., Jaen J.C., Liu J.,
RA   Monshouwer M., McMinn D., Rew Y., Sudom A., Sun D., Tu H., Ursu S.,
RA   Walker N., Yan X., Ye Q., Powers J.P.;
RT   "Discovery of novel, potent benzamide inhibitors of 11beta-
RT   hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral
RT   activity in an enzyme inhibition ex vivo model.";
RL   J. Med. Chem. 51:3953-3960(2008).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 24-292 IN COMPLEX WITH NADP
RP   AND INHIBITOR.
RX   PubMed=19217779; DOI=10.1016/j.bmcl.2009.01.058;
RA   Rew Y., McMinn D.L., Wang Z., He X., Hungate R.W., Jaen J.C.,
RA   Sudom A., Sun D., Tu H., Ursu S., Villemure E., Walker N.P.C., Yan X.,
RA   Ye Q., Powers J.P.;
RT   "Discovery and optimization of piperidyl benzamide derivatives as a
RT   novel class of 11beta-HSD1 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 19:1797-1801(2009).
RN   [19]
RP   VARIANT [LARGE SCALE ANALYSIS] GLU-148.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Catalyzes reversibly the conversion of cortisol to the
CC       inactive metabolite cortisone. Catalyzes reversibly the conversion
CC       of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact
CC       cells, the reaction runs only in one direction, from 7-
CC       ketocholesterol to 7-beta-hydroxycholesterol (By similarity).
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: An 11-beta-hydroxysteroid + NADP(+) = an 11-
CC       oxosteroid + NADPH. {ECO:0000269|PubMed:10497248,
CC       ECO:0000269|PubMed:15152005, ECO:0000269|PubMed:17070044,
CC       ECO:0000269|PubMed:17919905}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15513927,
CC       ECO:0000269|PubMed:17919905, ECO:0000269|PubMed:18069989,
CC       ECO:0000269|PubMed:18485702, ECO:0000269|PubMed:18553955,
CC       ECO:0000269|PubMed:19217779}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:10497248}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:10497248}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest expression in liver.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:10497248,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- DISEASE: Cortisone reductase deficiency (CRD) [MIM:604931]: In
CC       CRD, activation of cortisone to cortisol does not occur, resulting
CC       in adrenocorticotropin-mediated androgen excess and a phenotype
CC       resembling polycystic ovary syndrome (PCOS).
CC       {ECO:0000269|PubMed:12858176}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases
CC       (SDR) family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M76665; AAC31757.1; -; Genomic_DNA.
DR   EMBL; M76661; AAC31757.1; JOINED; Genomic_DNA.
DR   EMBL; M76662; AAC31757.1; JOINED; Genomic_DNA.
DR   EMBL; M76663; AAC31757.1; JOINED; Genomic_DNA.
DR   EMBL; M76664; AAC31757.1; JOINED; Genomic_DNA.
DR   EMBL; AY044084; AAK83653.1; -; Genomic_DNA.
DR   EMBL; AY044083; AAK83653.1; JOINED; Genomic_DNA.
DR   EMBL; AK313973; BAG36688.1; -; mRNA.
DR   EMBL; AL022398; CAA18541.2; -; Genomic_DNA.
DR   EMBL; AL031316; CAA18541.2; JOINED; Genomic_DNA.
DR   EMBL; AL031316; CAI20063.1; -; Genomic_DNA.
DR   EMBL; AL022398; CAI20063.1; JOINED; Genomic_DNA.
DR   EMBL; CH471100; EAW93445.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93446.1; -; Genomic_DNA.
DR   EMBL; BC012593; AAH12593.1; -; mRNA.
DR   CCDS; CCDS1489.1; -.
DR   PIR; A41173; DXHUBH.
DR   RefSeq; NP_001193670.1; NM_001206741.1.
DR   RefSeq; NP_005516.1; NM_005525.3.
DR   RefSeq; NP_861420.1; NM_181755.2.
DR   UniGene; Hs.195040; -.
DR   PDB; 1XU7; X-ray; 1.80 A; A/B/C/D=24-292.
DR   PDB; 1XU9; X-ray; 1.55 A; A/B/C/D=24-292.
DR   PDB; 2BEL; X-ray; 2.11 A; A/B/C/D=26-284.
DR   PDB; 2ILT; X-ray; 2.30 A; A=24-285.
DR   PDB; 2IRW; X-ray; 3.10 A; A/B/C/D/E/F/G/H=26-289.
DR   PDB; 2RBE; X-ray; 1.90 A; A/B/C/D=25-292.
DR   PDB; 3BYZ; X-ray; 2.69 A; A/B/C/D=25-292.
DR   PDB; 3BZU; X-ray; 2.25 A; A/B/C/D=24-292.
DR   PDB; 3CH6; X-ray; 2.35 A; A/B/D/E=24-292.
DR   PDB; 3CZR; X-ray; 2.35 A; A/B=24-292.
DR   PDB; 3D3E; X-ray; 2.60 A; A/B/C/D=24-292.
DR   PDB; 3D4N; X-ray; 2.50 A; A/B/C/D=24-292.
DR   PDB; 3D5Q; X-ray; 2.55 A; A/B/C/D=24-292.
DR   PDB; 3EY4; X-ray; 3.00 A; A/B/C/D=25-292.
DR   PDB; 3FCO; X-ray; 2.65 A; A/B=24-291.
DR   PDB; 3FRJ; X-ray; 2.30 A; A/B=24-292.
DR   PDB; 3H6K; X-ray; 2.19 A; A/B/C/D=24-292.
DR   PDB; 3HFG; X-ray; 2.30 A; A/B/C/D=24-292.
DR   PDB; 3OQ1; X-ray; 2.60 A; A/B/C/D=24-292.
DR   PDB; 3PDJ; X-ray; 2.30 A; A/B=24-292.
DR   PDB; 3QQP; X-ray; 2.72 A; A/B/C/D=24-292.
DR   PDB; 3TFQ; X-ray; 1.80 A; A/B/D/E=24-292.
DR   PDB; 4BB5; X-ray; 2.20 A; A/B/C/D=1-292.
DR   PDB; 4BB6; X-ray; 2.55 A; A/B=1-292.
DR   PDB; 4C7J; X-ray; 2.16 A; A/B/C/D=24-292.
DR   PDB; 4C7K; X-ray; 1.91 A; A/B/C/D=24-292.
DR   PDB; 4HFR; X-ray; 2.73 A; A/B=24-292.
DR   PDB; 4HX5; X-ray; 2.19 A; A/B/C/D=24-292.
DR   PDB; 4IJU; X-ray; 2.35 A; A/B/D/E=24-292.
DR   PDB; 4IJV; X-ray; 2.35 A; A/B/D/E=24-292.
DR   PDB; 4IJW; X-ray; 2.35 A; A/B/D/E=24-292.
DR   PDB; 4K1L; X-ray; 1.96 A; A/B/C/D=24-292.
DR   PDB; 4P38; X-ray; 2.80 A; A/B=26-290.
DR   PDB; 4YYZ; X-ray; 3.20 A; A/B=26-284.
DR   PDBsum; 1XU7; -.
DR   PDBsum; 1XU9; -.
DR   PDBsum; 2BEL; -.
DR   PDBsum; 2ILT; -.
DR   PDBsum; 2IRW; -.
DR   PDBsum; 2RBE; -.
DR   PDBsum; 3BYZ; -.
DR   PDBsum; 3BZU; -.
DR   PDBsum; 3CH6; -.
DR   PDBsum; 3CZR; -.
DR   PDBsum; 3D3E; -.
DR   PDBsum; 3D4N; -.
DR   PDBsum; 3D5Q; -.
DR   PDBsum; 3EY4; -.
DR   PDBsum; 3FCO; -.
DR   PDBsum; 3FRJ; -.
DR   PDBsum; 3H6K; -.
DR   PDBsum; 3HFG; -.
DR   PDBsum; 3OQ1; -.
DR   PDBsum; 3PDJ; -.
DR   PDBsum; 3QQP; -.
DR   PDBsum; 3TFQ; -.
DR   PDBsum; 4BB5; -.
DR   PDBsum; 4BB6; -.
DR   PDBsum; 4C7J; -.
DR   PDBsum; 4C7K; -.
DR   PDBsum; 4HFR; -.
DR   PDBsum; 4HX5; -.
DR   PDBsum; 4IJU; -.
DR   PDBsum; 4IJV; -.
DR   PDBsum; 4IJW; -.
DR   PDBsum; 4K1L; -.
DR   PDBsum; 4P38; -.
DR   PDBsum; 4YYZ; -.
DR   ProteinModelPortal; P28845; -.
DR   SMR; P28845; -.
DR   BioGrid; 109523; 15.
DR   DIP; DIP-59618N; -.
DR   IntAct; P28845; 1.
DR   STRING; 9606.ENSP00000261465; -.
DR   BindingDB; P28845; -.
DR   ChEMBL; CHEMBL4235; -.
DR   DrugBank; DB07049; (2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB03814; 2-(N-Morpholino)-Ethanesulfonic Acid.
DR   DrugBank; DB02329; Carbenoxolone.
DR   DrugBank; DB05064; INCB13739.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00635; Prednisone.
DR   GuidetoPHARMACOLOGY; 2763; -.
DR   SwissLipids; SLP:000000809; -.
DR   iPTMnet; P28845; -.
DR   PhosphoSitePlus; P28845; -.
DR   BioMuta; HSD11B1; -.
DR   DMDM; 118569; -.
DR   PaxDb; P28845; -.
DR   PeptideAtlas; P28845; -.
DR   PRIDE; P28845; -.
DR   DNASU; 3290; -.
DR   Ensembl; ENST00000367027; ENSP00000355994; ENSG00000117594.
DR   Ensembl; ENST00000367028; ENSP00000355995; ENSG00000117594.
DR   GeneID; 3290; -.
DR   KEGG; hsa:3290; -.
DR   CTD; 3290; -.
DR   DisGeNET; 3290; -.
DR   GeneCards; HSD11B1; -.
DR   HGNC; HGNC:5208; HSD11B1.
DR   HPA; HPA047729; -.
DR   MalaCards; HSD11B1; -.
DR   MIM; 600713; gene.
DR   MIM; 604931; phenotype.
DR   neXtProt; NX_P28845; -.
DR   OpenTargets; ENSG00000117594; -.
DR   Orphanet; 168588; Hyperandrogenism due to cortisone reductase deficiency.
DR   PharmGKB; PA29476; -.
DR   eggNOG; KOG1205; Eukaryota.
DR   eggNOG; COG1028; LUCA.
DR   GeneTree; ENSGT00870000136396; -.
DR   HOGENOM; HOG000010276; -.
DR   HOVERGEN; HBG005481; -.
DR   InParanoid; P28845; -.
DR   KO; K15680; -.
DR   OMA; FMAYYYY; -.
DR   OrthoDB; EOG091G0H0R; -.
DR   PhylomeDB; P28845; -.
DR   TreeFam; TF329114; -.
DR   BioCyc; MetaCyc:HS04154-MONOMER; -.
DR   BRENDA; 1.1.1.146; 2681.
DR   BRENDA; 1.1.1.B40; 2681.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   SABIO-RK; P28845; -.
DR   ChiTaRS; HSD11B1; human.
DR   EvolutionaryTrace; P28845; -.
DR   GeneWiki; 11%CE%B2-hydroxysteroid_dehydrogenase_type_1; -.
DR   GenomeRNAi; 3290; -.
DR   PRO; PR:P28845; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117594; -.
DR   CleanEx; HS_HSD11B1; -.
DR   ExpressionAtlas; P28845; baseline and differential.
DR   Genevisible; P28845; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0070524; F:11-beta-hydroxysteroid dehydrogenase (NADP+) activity; IEA:UniProtKB-EC.
DR   GO; GO:0003845; F:11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity; TAS:Reactome.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR020904; Sc_DH/Rdtase_CS.
DR   InterPro; IPR002347; SDR_fam.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00061; ADH_SHORT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Endoplasmic reticulum; Glycoprotein;
KW   Lipid metabolism; Membrane; NADP; Oxidoreductase; Polymorphism;
KW   Reference proteome; Signal-anchor; Steroid metabolism; Transmembrane;
KW   Transmembrane helix.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:Q6R0J2}.
FT   CHAIN         2    292       Corticosteroid 11-beta-dehydrogenase
FT                                isozyme 1.
FT                                /FTId=PRO_0000054619.
FT   TOPO_DOM      2      7       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      8     24       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     25    292       Lumenal. {ECO:0000255}.
FT   NP_BIND      41     67       NADP. {ECO:0000269|PubMed:15513927,
FT                                ECO:0000269|PubMed:17919905,
FT                                ECO:0000269|PubMed:18069989,
FT                                ECO:0000269|PubMed:18485702,
FT                                ECO:0000269|PubMed:18553955,
FT                                ECO:0000269|PubMed:19217779}.
FT   NP_BIND      92     93       NADP. {ECO:0000269|PubMed:15513927,
FT                                ECO:0000269|PubMed:17919905,
FT                                ECO:0000269|PubMed:18069989,
FT                                ECO:0000269|PubMed:18485702,
FT                                ECO:0000269|PubMed:18553955,
FT                                ECO:0000269|PubMed:19217779}.
FT   NP_BIND     119    121       NADP. {ECO:0000269|PubMed:15513927,
FT                                ECO:0000269|PubMed:17919905,
FT                                ECO:0000269|PubMed:18069989,
FT                                ECO:0000269|PubMed:18485702,
FT                                ECO:0000269|PubMed:18553955,
FT                                ECO:0000269|PubMed:19217779}.
FT   NP_BIND     183    187       NADP. {ECO:0000269|PubMed:15513927,
FT                                ECO:0000269|PubMed:17919905,
FT                                ECO:0000269|PubMed:18069989,
FT                                ECO:0000269|PubMed:18485702,
FT                                ECO:0000269|PubMed:18553955,
FT                                ECO:0000269|PubMed:19217779}.
FT   NP_BIND     218    222       NADP. {ECO:0000269|PubMed:15513927,
FT                                ECO:0000269|PubMed:17919905,
FT                                ECO:0000269|PubMed:18069989,
FT                                ECO:0000269|PubMed:18485702,
FT                                ECO:0000269|PubMed:18553955,
FT                                ECO:0000269|PubMed:19217779}.
FT   ACT_SITE    183    183       Proton acceptor.
FT   BINDING     170    170       Substrate.
FT   CARBOHYD    123    123       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    162    162       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    207    207       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT     148    148       V -> E (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035845.
FT   MUTAGEN       5      6       KK->RR: Predominantly inverted topology.
FT                                No effect on activity.
FT                                {ECO:0000269|PubMed:10497248,
FT                                ECO:0000269|PubMed:15152005}.
FT   MUTAGEN       5      6       KK->SS: Inverted topology. Reduced Vmax.
FT                                {ECO:0000269|PubMed:10497248,
FT                                ECO:0000269|PubMed:15152005}.
FT   MUTAGEN       5      5       K->R: Predominantly inverted topology. No
FT                                effect on activity.
FT                                {ECO:0000269|PubMed:10497248}.
FT   MUTAGEN       5      5       K->S: Inverted topology. No effect on
FT                                activity. {ECO:0000269|PubMed:10497248}.
FT   MUTAGEN       6      6       K->R: No effect on topology. Increased Km
FT                                for corticosterone.
FT                                {ECO:0000269|PubMed:10497248}.
FT   MUTAGEN       6      6       K->S: No effect on topology or activity.
FT                                {ECO:0000269|PubMed:10497248}.
FT   MUTAGEN      18     21       YYYY->AAAA: No effect on topology.
FT                                Reduced Vmax.
FT                                {ECO:0000269|PubMed:10497248}.
FT   MUTAGEN      18     21       YYYY->FFFF: No effect on topology or
FT                                activity. {ECO:0000269|PubMed:10497248}.
FT   MUTAGEN      19     21       YYY->AYA: No effect on topology. Reduced
FT                                Vmax. {ECO:0000269|PubMed:10497248}.
FT   MUTAGEN      25     26       EE->KK: Inverted topology. Reduced Vmax.
FT                                {ECO:0000269|PubMed:15152005}.
FT   MUTAGEN      25     26       EE->KQ: No effect on topology. Reduced
FT                                Vmax. {ECO:0000269|PubMed:15152005}.
FT   MUTAGEN      25     26       EE->QQ: Reduced Vmax.
FT                                {ECO:0000269|PubMed:15152005}.
FT   MUTAGEN      25     25       E->K,Q: No effect on activity.
FT                                {ECO:0000269|PubMed:15152005}.
FT   MUTAGEN      26     26       E->K: No effect on activity.
FT                                {ECO:0000269|PubMed:15152005}.
FT   MUTAGEN      35     36       KK->SS: Complete loss of activity.
FT                                {ECO:0000269|PubMed:15152005}.
FT   HELIX        29     32       {ECO:0000244|PDB:1XU9}.
FT   STRAND       36     41       {ECO:0000244|PDB:1XU9}.
FT   HELIX        45     56       {ECO:0000244|PDB:1XU9}.
FT   STRAND       60     66       {ECO:0000244|PDB:1XU9}.
FT   HELIX        68     81       {ECO:0000244|PDB:1XU9}.
FT   STRAND       84     90       {ECO:0000244|PDB:1XU9}.
FT   STRAND       93     95       {ECO:0000244|PDB:4YYZ}.
FT   HELIX        96    110       {ECO:0000244|PDB:1XU9}.
FT   STRAND      114    118       {ECO:0000244|PDB:1XU9}.
FT   HELIX       133    143       {ECO:0000244|PDB:1XU9}.
FT   HELIX       145    161       {ECO:0000244|PDB:1XU9}.
FT   STRAND      164    170       {ECO:0000244|PDB:1XU9}.
FT   HELIX       171    173       {ECO:0000244|PDB:1XU9}.
FT   HELIX       181    204       {ECO:0000244|PDB:1XU9}.
FT   STRAND      209    215       {ECO:0000244|PDB:1XU9}.
FT   HELIX       221    226       {ECO:0000244|PDB:1XU9}.
FT   HELIX       229    234       {ECO:0000244|PDB:1XU9}.
FT   HELIX       238    250       {ECO:0000244|PDB:1XU9}.
FT   STRAND      254    258       {ECO:0000244|PDB:1XU9}.
FT   HELIX       262    267       {ECO:0000244|PDB:1XU9}.
FT   HELIX       271    280       {ECO:0000244|PDB:1XU9}.
FT   HELIX       281    283       {ECO:0000244|PDB:1XU9}.
FT   HELIX       287    290       {ECO:0000244|PDB:4C7J}.
SQ   SEQUENCE   292 AA;  32401 MW;  4632D0F3BBEFC474 CRC64;
     MAFMKKYLLP ILGLFMAYYY YSANEEFRPE MLQGKKVIVT GASKGIGREM AYHLAKMGAH
     VVVTARSKET LQKVVSHCLE LGAASAHYIA GTMEDMTFAE QFVAQAGKLM GGLDMLILNH
     ITNTSLNLFH DDIHHVRKSM EVNFLSYVVL TVAALPMLKQ SNGSIVVVSS LAGKVAYPMV
     AAYSASKFAL DGFFSSIRKE YSVSRVNVSI TLCVLGLIDT ETAMKAVSGI VHMQAAPKEE
     CALEIIKGGA LRQEEVYYDS SLWTTLLIRN PCRKILEFLY STSYNMDRFI NK
//
